Autolus Therapeutics announces pivotal Phase 2 FELIX clinical trial has met primary endpoint at interim analysis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/31/2026

1. PCG
2. NVDA
3. AVGO
4. ALNY
5. CNS
6. SPCX
7. APO
8. SRE
9. ATTO
10. BRVE

Go back to Autolus Therapeutics announces pivotal Phase 2 FELIX clinical trial has met primary endpoint at interim analysis
(NASDAQ: AUTL) Delayed: 2.34 --0 (-0%)
Previous Close $2.34    52 Week High $ 
Open $2.32    52 Week Low $ 
Day High $2.34    P/E N/A 
Day Low $2.30    EPS $ 
Volume 529,887